Polymorphisms of MUC16 (CA125) and MUC1 (CA15.3) in relation to ovarian cancer risk and survival

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Williams, Kristina A ^a,b   Terry, Kathryn L ^a,b,c   Tworoger, Shelley S ^a,c   Vitonis, Allison F ^a   Titus, Linda J ^d   Cramer, Daniel W ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; MUCIN 1;

ADULT; AGE; ANTIBODY BLOOD LEVEL; ARTICLE; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENOTYPING TECHNIQUE; HIGH RISK PATIENT; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MUC1 GENE; MUC16 GENE; OVARY CANCER; OVERALL SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADENOCARCINOMA, MUCINOUS; AGE FACTORS; AGED; CA-125 ANTIGEN; CARCINOMA, ENDOMETRIOID; CASE-CONTROL STUDIES; CYSTADENOMA, SEROUS; FEMALE; HOMOZYGOTE; HUMANS; MEMBRANE PROTEINS; MIDDLE AGED; MUCIN-1; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84895778937     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088334     Document Type: Article

References (41)

1. Hattrup CL, Gendler SJ (2008) Structure and function of the cell surface (tethered) mucins. Annu Rev Physiol 70: 431-457. (Pubitemid 351738187)
2. Bast RC, Jr., Klug TL, St John E, Jenison E, Niloff JM, et al. (1983) A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309: 883-887. (Pubitemid 13014028)
3. Buller RE, Berman ML, Bloss JD, Manetta A, DiSaia PJ (1992) Serum CA125 regression in epithelial ovarian cancer: correlation with reassessment findings and survival. Gynecol Oncol 47: 87-92.
4. Giuntoli RL, 2nd, Rodriguez GC, Whitaker RS, Dodge R, Voynow JA (1998) Mucin gene expression in ovarian cancers. Cancer Res 58: 5546-5550. (Pubitemid 28551143)
5. Wang L, Ma J, Liu F, Yu Q, Chu G, et al. (2007) Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance. Gynecol Oncol 105: 695-702. (Pubitemid 46734194)
6. Theriault C, Pinard M, Comamala M, Migneault M, Beaudin J, et al. (2011) MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis. Gynecol Oncol 121: 434-443.
7. Sellers TA, Huang Y, Cunningham J, Goode EL, Sutphen R, et al. (2008) Association of single nucleotide polymorphisms in glycosylation genes with risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 17: 397-404. (Pubitemid 351272793)
8. Phelan CM, Tsai YY, Goode EL, Vierkant RA, Fridley BL, et al. (2010) Polymorphism in the GALNT1 gene and epithelial ovarian cancer in non-Hispanic white women: the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev 19: 600-604.
9. Goode EL, Maurer MJ, Sellers TA, Phelan CM, Kalli KR, et al. (2010) Inherited determinants of ovarian cancer survival. Clin Cancer Res 16: 995-1007.
10. Terry KL, Vitonis AF, Hernandez D, Lurie G, Song H, et al. (2010) A polymorphism in the GALNT2 gene and ovarian cancer risk in four population based case-control studies. Int J Mol Epidemiol Genet 1: 272-277.
11. Harris HR, Cramer DW, Vitonis AF, DePari M, Terry KL (2012) Folate, vitamin B(6), vitamin B(12), methionine and alcohol intake in relation to ovarian cancer risk. Int J Cancer 131: E518-529.
12. Vitonis AF, Titus-Ernstoff L, Cramer DW (2011) Assessing ovarian cancer risk when considering elective oophorectomy at the time of hysterectomy. Obstet Gynecol 117: 1042-1050.
13. Tworoger SS, Gates MA, Lee IM, Buring JE, Titus-Ernstoff L, et al. (2009) Polymorphisms in the vitamin D receptor and risk of ovarian cancer in four studies. Cancer Res 69: 1885-1891.
14. Cramer DW, Vitonis AF, Welch WR, Terry KL, Goodman A, et al. (2010) Correlates of the preoperative level of CA125 at presentation of ovarian cancer. Gynecol Oncol 119: 462-468.
15. Skates SJ, Mai P, Horick NK, Piedmonte M, Drescher CW, et al. (2011) Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status. Cancer Prev Res (Phila) 4: 1401-1408.
16. Bon GG, Kenemans P, Dekker JJ, Hompes PG, Verstraeten RA, et al. (1999) Fluctuations in CA 125 and CA 15-3 serum concentrations during spontaneous ovulatory cycles. Hum Reprod 14: 566-570. (Pubitemid 29097419)
17. Takano M, Fujii K, Kita T, Kikuchi Y, Uchida K (2004) Amplicon profiling reveals cytoplasmic overexpression of MUC1 protein as an indicator of resistance to platinum-based chemotherapy in patients with ovarian cancer. Oncol Rep 12: 1177-1182.
18. Wreesmann VB, Sieczka EM, Socci ND, Hezel M, Belbin TJ, et al. (2004) Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker. Cancer Res 64: 3780-3789. (Pubitemid 38697287)
19. Myllykangas S, Junnila S, Kokkola A, Autio R, Scheinin I, et al. (2008) Integrated gene copy number and expression microarray analysis of gastric cancer highlights potential target genes. Int J Cancer 123: 817-825. (Pubitemid 352032407)
20. Lacunza E, Baudis M, Colussi AG, Segal-Eiras A, Croce MV, et al. (2010) MUC1 oncogene amplification correlates with protein overexpression in invasive breast carcinoma cells. Cancer Genet Cytogenet 201: 102-110.
21. Bieche I, Lidereau R (1997) A gene dosage effect is responsible for high overexpression of the MUC1 gene observed in human breast tumors. Cancer Genet Cytogenet 98: 75-80. (Pubitemid 27400856)
22. Waltz MR, Pandelidis SM, Pratt W, Barnes D, Swallow DM, et al. (1998) A microsatellite within the MUC1 locus at 1q21 is altered in the neoplastic cells of breast cancer patients. Cancer Genet Cytogenet 100: 63-67. (Pubitemid 128766345)
23. Schroeder JA, Masri AA, Adriance MC, Tessier JC, Kotlarczyk KL, et al. (2004) MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation. Oncogene 23: 5739-5747. (Pubitemid 39093019)
24. Feng H, Ghazizadeh M, Konishi H, Araki T (2002) Expression of MUC1 and MUC2 mucin gene products in human ovarian carcinomas. Jpn J Clin Oncol 32: 525-529. (Pubitemid 43102758)
25. Tashiro Y, Yonezawa S, Kim YS, Sato E (1994) Immunohistochemical study of mucin carbohydrates and core proteins in human ovarian tumors. Hum Pathol 25: 364-372. (Pubitemid 24151121)
26. Palmer AJ, Lochhead P, Hold GL, Rabkin CS, Chow WH, et al. (2012) Genetic variation in C20orf54, PLCE1 and MUC1 and the risk of upper gastrointestinal cancers in Caucasian populations. Eur J Cancer Prev 21: 541-544.
27. Li FX, Yang XX, He XQ, Hu NY, Wu YS, et al. (2012) Association of 10q23 with colorectal cancer in a Chinese population. Mol Biol Rep 39: 9557-9562.
28. Horimasu Y, Hattori N, Ishikawa N, Kawase S, Tanaka S, et al. (2012) Different MUC1 gene polymorphisms in German and Japanese ethnicities affect serum KL-6 levels. Respir Med 106: 1756-1764.
29. Ng W, Loh AX, Teixeira AS, Pereira SP, Swallow DM (2008) Genetic regulation of MUC1 alternative splicing in human tissues. Br J Cancer 99: 978-985.
30. Marin F, Bonet C, Munoz X, Garcia N, Pardo ML, et al. (2012) Genetic variation in MUC1, MUC2 and MUC6 genes and evolution of gastric cancer precursor lesions in a long-term follow-up in a high-risk area in Spain. Carcinogenesis 33: 1072-1080.
31. Saeki N, Saito A, Choi IJ, Matsuo K, Ohnami S, et al. (2011) A functional single nucleotide polymorphism in mucin 1, at chromosome 1q22, determines susceptibility to diffuse-type gastric cancer. Gastroenterology 140: 892-902.
32. Shi Y, Hu Z, Wu C, Dai J, Li H, et al. (2011) A genome-wide association study identifies new susceptibility loci for non-cardia gastric cancer at 3q13.31 and 5p13.1. Nat Genet 43: 1215-1218.
33. Feng H, Ghazizadeh M, Konishi H, Araki T (2002) Expression of MUC1 and MUC2 mucin gene products in human ovarian carcinomas. Japanese journal of clinical oncology 32: 525-529. (Pubitemid 43102758)
34. Tothill RW, Tinker AV, George J, Brown R, Fox SB, et al. (2008) Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14: 5198-5208.
35. Pejovic T, Heim S, Mandahl N, Baldetorp B, Elmfors B, et al. (1992) Chromosome aberrations in 35 primary ovarian carcinomas. Genes Chromosomes Cancer 4: 58-68.
36. Thompson FH, Liu Y, Emerson J, Weinstein R, Makar R, et al. (1994) Simple numeric abnormalities as primary karyotype changes in ovarian carcinoma. Genes Chromosomes Cancer 10: 262-266. (Pubitemid 24238434)
37. Micci F, Weimer J, Haugom L, Skotheim RI, Grunewald R, et al. (2009) Reverse painting of microdissected chromosome 19 markers in ovarian carcinoma identifies a complex rearrangement map. Genes Chromosomes Cancer 48: 184-193.
38. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, et al. (2001) dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 29: 308-311. (Pubitemid 32054478)
39. Bouanene H, Hadj Kacem H, Ben Fatma L, Ben Limem H, Ben Ahmed S, et al. (2011) Polymorphisms in the MUC16 gene: potential implication in epithelial ovarian cancer. Pathol Oncol Res 17: 295-299.
40. Carraway KL, Hull SR (1989) O-glycosylation pathway for mucin-type glycoproteins. Bioessays 10: 117-121.
41. Tabor HK, Risch NJ, Myers RM (2002) Candidate-gene approaches for studying complex genetic traits: practical considerations. Nat Rev Genet 3: 391-397. (Pubitemid 34506720)